Title : ( Salts and Cocrystals of Antidiabetic Drugs, Gliclazide, Tolbutamide and Glipizide: Solubility Enhancements through Drug-Coformer Interactions )
Authors: ali samie , G. R. Desiraju , M. Banik ,
دانلود فایل برای اعضای دانشگاهAccess to full-text not allowed by authors
Abstract
Gliclazide (GCZ), tolbutamide (TOL) and glipizide (GPZ) are BCS class IIantidiabetic drugs with poor aqueous solubility. Multicomponent solid forms, salts, and cocrystals of GCZ were obtained upon liquid assisted grinding with coformers of catechol (CAT), resorcinol (RES), p- toluenesulfonic acid (PTSA) and piperazine (PPZ). The solubility of TOL was also modified by salt formation with PPZ. The multicomponent solids were characterized by single crystal X-ray diffraction (SCXRD), powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC) and thermal gravimetric analysis (TGA) and further subjected to solubility studies. The cocrystals/salts, in all cases, showed improvements in the solubility and dissolution rates compared to the parent APIs. GCZ−PPZ and TOL−PPZ(I) showed 6.6 and 80 and foldenhancements respectively in the solubility. The reasons for the improved solubility of the cocrystals/salts in terms of drug-coformer interactions are discussed.
Keywords
, Salts و Cocrystals of Antidiabetic Drugs, Gliclazide, Tolbutamide
@article{paperid:1068365,
author = {Samie, Ali and and },
title = {Salts and Cocrystals of Antidiabetic Drugs, Gliclazide, Tolbutamide and Glipizide: Solubility Enhancements through Drug-Coformer Interactions},
journal = {Crystal Growth and Design},
year = {2017},
volume = {17},
number = {5},
month = {April},
issn = {1528-7483},
pages = {2406--2417},
numpages = {11},
keywords = {Salts و Cocrystals of Antidiabetic Drugs; Gliclazide; Tolbutamide},
}
%0 Journal Article
%T Salts and Cocrystals of Antidiabetic Drugs, Gliclazide, Tolbutamide and Glipizide: Solubility Enhancements through Drug-Coformer Interactions
%A Samie, Ali
%A
%A
%J Crystal Growth and Design
%@ 1528-7483
%D 2017
